Geninus Inc. (389030) fair value: what the stock is really worth
As of Oct 27, 2026: fair value (intrinsic value) of Geninus Inc. stock KRW 150, price KRW 1,335, upside -88.8%, quality 36 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Fair value above price?No
Good quality?No
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 26, 2026.
How to read this chart
60‑month range 1,080 KRW – 6,270 KRW · fair‑value band 111.79 KRW – 223.58 KRW · the 1,335 KRW price screens above the 149.80 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Oct 26, 2026.
Follow Geninus in your weekly email
Every Wednesday you see whether Geninus is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
GENINUS Inc., a bioinformation analysis company, engages in the research and development, manufacture, and sale of genome analysis solutions in South Korea, the United States, and Asia.
Show moreShow less
It offers tarhet and biomarker discovery; AI digital pathology; single cell analysis; and spatial and in-situ transcriptomics services; and SPACEINSIGHT, a cutting-edge cloud based integrated analysis platform. It serves hospitals, pharmaceutical companies, and researchers.
The company was founded in 2018 and is headquartered in Seoul, South Korea.
Stock analysis
Geninus Inc. (389030) currently trades at 1,335 KRW, while our model-based Fair Value estimate is 149.80 KRW, 88.8% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the data coverage at low.
Scenario range: 111.79 KRW (bear) to 223.58 KRW (bull), the price of 1,335 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 36/100 (below-average quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Geninus Inc. reported revenue of 10.5B KRW in FY2025 versus 8.1B KRW in FY2021, a compound +6.5%/yr. Reported net income was −17.4B KRW in FY2025.
Our AI-assisted moat analysis scores the competitive advantage at 9 out of 100 (medium confidence).
What moves the price
The share trades about 79% below its 52-week high and at its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 4% fair-value upside, at −89%, 389030 screens richer than that median.
Fair Value models
Bear111.79 KRWFair Value 149.80 KRWBull223.58 KRW
Price 1,335 KRW · Upside -88.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.35/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+62.4%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+1.3%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.5%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+40.3%
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−99.2% (2020) → −111.3% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 600 stocks
Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score36 · Below median
Fair Value upside−88.8% · Bottom 25%
Profitability
Return on assets−44.2% · Bottom 25%
Net margin (12 months)−180.5% · Bottom 25%
Operating margin (12 months)−127.4% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)40.3% · Top 25%
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B5.76× · Priciest 25%
P/S (12 months)4.65× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)100· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)100· sector 97
DIVIDEND (yield)0· sector 24
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Geninus Inc. Fair Value". https://www.fairvalue-calculator.com/stock/389030
Frequently asked questions
Is Geninus Inc. (389030) overvalued or undervalued?
As of Oct 26, 2026, our model estimates a fair value of 149.80 KRW versus a price of 1,335 KRW, about −89% upside (overvalued).
What is the fair value of 389030?
Our model-based fair value for Geninus Inc. is 149.80 KRW (as of Oct 26, 2026), built from audited fundamentals. The current price: 1,335 KRW.
What is the quality score of 389030?
Geninus Inc. has a Quality Score of 36/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Geninus Inc. (389030)?
Our model-based price target is the fair value of 149.80 KRW (as of Oct 26, 2026) from 1 valuation models. Cautious scenario 111.79 KRW, optimistic scenario 223.58 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Geninus Inc. stock forecast for 2026?
Our models put fair value at 149.80 KRW, about −89% upside versus a price of 1,335 KRW (overvalued). Cautious scenario 111.79 KRW, optimistic scenario 223.58 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Geninus Inc. (389030)?
Geninus Inc. reported trailing-twelve-month revenue of about 11.3B KRW (latest available figure, as of Oct 26, 2026).
What is the intrinsic value of Geninus Inc. (389030)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Geninus Inc. it is 149.80 KRW per share (as of Oct 26, 2026), against a price of 1,335 KRW. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Geninus Inc. stock overvalued or undervalued in 2026?
As of Oct 26, 2026, 389030 trades above its calculated fair value: price 1,335 KRW, fair value 149.80 KRW, a gap of about −89% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 389030?
No. The price is what the market pays today (1,335 KRW); the fair value is what the company's own numbers justify (149.80 KRW). For Geninus Inc. the two are 1,185 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Geninus Inc. worth?
The market values Geninus Inc. at about 52.4B KRW (market capitalisation, as of Oct 26, 2026). Per share that is 1,335 KRW; our models calculate a fair value of 149.80 KRW per share.
What do the bullish and bearish scenarios say about 389030?
Our models span a range for Geninus Inc.: cautious scenario 111.79 KRW, base 149.80 KRW, optimistic 223.58 KRW per share (as of Oct 26, 2026, price 1,335 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Geninus Inc. (389030)?
Balance-sheet figures for Geninus Inc. (as of Oct 26, 2026): return on equity −72.4%. They feed the Quality Score of 36/100, which measures business quality independently of the share price.
How far is 389030 from its 52-week high?
Geninus Inc. trades at 1,335 KRW, about 79% below its 52-week high of 6,270 KRW and at the low of 1,335 KRW (as of Oct 27, 2026). Distance from the high says nothing about value: that is what the fair value of 149.80 KRW is for.
Which stocks are comparable to Geninus Inc.?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Geninus Inc. stock attractive at the current price?
The data as of Oct 26, 2026: price 1,335 KRW, calculated fair value 149.80 KRW (−89%), Quality Score 36/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 389030 calculated?
We run Geninus Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 149.80 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Geninus Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Geninus Inc. (389030)?
The closing price on Oct 27, 2026 was 1,335 KRW. Our model-based fair value is 149.80 KRW, about −89% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Geninus Inc. right now?
The price sits above even our optimistic bull case (223.58 KRW). The favourable scenario is already priced in. Weak quality (36/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (111.79 KRW to 223.58 KRW) leaves room in how you read the outcome.
Key figures of Geninus Inc.
How large is the market capitalisation of Geninus Inc. (389030)?
The market capitalisation of Geninus Inc. is 52.4B KRW (≈ $39.1M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Geninus Inc. (389030)?
The price-to-sales ratio of Geninus Inc. is 7.27 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the return on equity of Geninus Inc. (389030)?
The return on equity (ROE) of Geninus Inc. is −72.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Geninus Inc. (389030)?
On an EBIT basis the return on assets of Geninus Inc. is −25.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Geninus Inc. (389030)?
The operating margin of Geninus Inc. is −127% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Geninus Inc. (389030)?
Revenue at Geninus Inc. is growing +40.3% versus a year earlier (3y avg +1.3%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Geninus Inc. (389030) generate?
The free cash flow of Geninus Inc. is −8.5B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Geninus Inc. (389030) carry?
The net debt of Geninus Inc. is 1.4B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Geninus Inc. in the live analysis
One click puts Geninus Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 26, 2026